Cortical acetylcholine (ACh) has been shown to regulate diverse cognitive processes and its release can be regulated by neuromodulators that act presynaptically at cholinergic terminals. The neocortex receives dense glutamatergic input from thalamocortical and other ®bres. The present study used in vivo microdialysis to examine, and pharmacologically characterize, the effect of glutamate on cortical ACh release evoked by electrical stimulation of the pedunculopontine tegmental nucleus in urethane-anaesthetized rats. All drugs were administered locally within the cortex by reverse dialysis. Application of glutamate had no detectable effect on spontaneous ACh release but reduced evoked cortical ACh ef¯ux in a concentration-dependent manner. This effect was mimicked by the glutamate transporter blocker L-trans-pyrrolidine-2,4-dicarboxylic acid, as well as by the ionotropic glutamate receptor agonists N-methyl-D-aspartic acid and a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid, and was blocked by the ionotropic glutamate receptor antagonists 6,7-dinitroquinoxaline-2,3-dione and (+/±)-3-(2-carboxypiperazin4yl)-propyl-1-phosphonic acid. Glutamate application also increased extracellular adenosine levels but the simultaneous delivery of the broad-spectrum adenosine receptor antagonist caffeine failed to affect the inhibitory action of glutamate on evoked ACh release. However, the effect of glutamate was fully blocked by simultaneous delivery of the GABA A receptor antagonist bicuculline and partially blocked by the GABA B receptor antagonist phaclofen. These results suggest that ionotropic glutamate receptor activation by glutamate inhibits evoked cortical ACh release via an indirect pathway involving GABAergic neurons in the cortex.
Introduction
Cortical acetylcholine (ACh) has been implicated in attention (for a review, see Acquas et al., 1996; Sarter & Bruno, 2000) , plasticity (Baskerville et al., 1997) , facilitation of sensory information processing (Rasmusson, 1993) , and cortical activation during wakefulness and rapid eye movement sleep (Kanai & Szerb, 1965; Szerb, 1967; Jasper & Tessier, 1971) . Increases in cortical ACh ef¯ux alter the properties of postsynaptic neurons and their responses to other inputs. Local delivery of ACh enhances the response of cortical neurons to appropriate modality-speci®c stimuli in somatosensory (Donoghue & Carroll, 1987; Metherate et al., 1987) , auditory (Metherate & Weinberger, 1990 ) and visual cortices (Sillito & Kemp, 1983) . This suggests that factors that regulate cortical ACh ef¯ux could in¯uence cognitive processes and behaviour by modulating the activity of cortical neurons.
Cortical ACh is derived from the terminals of cholinergic neurons whose cell bodies are located within the basal forebrain (for a review, see Semba, 2000) . Therefore, the release of cortical ACh can be modulated at two levels. Firstly, cortical ACh release depends on the activity of cholinergic cells within the basal forebrain. Activation of cholinergic neurons by direct electrical stimulation (Rasmusson et al., 1992) , stimulation of afferents to the basal forebrain (Rasmusson et al., 1994) , or infusion of transmitters or analogs into the basal forebrain (Casamenti et al., 1986; Kurosawa et al., 1989; Bertorelli et al., 1991; Fadel et al., 2001) can alter cortical ACh release in vivo. A second mechanism for modulating ACh ef¯ux is through activation of presynaptic receptors located on intracortical cholinergic terminals. Previous in vivo studies have suggested that ACh ef¯ux is regulated presynaptically by a number of transmitters and modulators including serotonin (Crespi et al., 1997) , adenosine (Materi et al., 2000) , neurotensin (Lapchak et al., 1990) , noradrenaline (Beani et al., 1986; Tellez et al., 1997) , GABA (Giorgetti et al., 2000) and ACh (Marchi & Raiteri, 1985; Vannucchi & Pepeu, 1995) .
In the light of the fact that the cortex receives dense glutamatergic inputs from a number of subcortical regions including the thalamus, and the increasing evidence for extrasynaptic spillover of glutamate (for a review, see Bergles et al., 1999; Mitchell & Silver, 2000) , the possibility that this amino acid modulates cortical ACh release is worth considering. Studies using in vivo microdialysis in unanaesthetized rats demonstrated that intraperitoneal delivery of an NMDA receptor antagonist increased cortical ACh release, and this increase was antagonized by intracortical infusion of N-methyl-D-aspartate (NMDA; Hasegawa et al., 1993) . This result suggests that activation of cortical NMDA receptors might inhibit ACh release. However, in vitro studies using rat cortical slices have demonstrated that NMDA administration evokes ACh release (Lodge & Johnston, 1985; Ulus et al., 1992) . Because the level of cortical ACh ef¯ux could have profound effects on behaviour, this discrepancy requires further investigation.
To understand the role of glutamate in presynaptic modulation of cortical ACh release, the present study examined the effects of locally applied glutamate and speci®c receptor agonists and antagonists on ACh ef¯ux using an established model of brainstem stimulationinduced cortical ACh release (Rasmusson et al., 1994) . Preliminary results have been reported in abstract form (Materi & Semba, 1999) .
Materials and methods
All experiments were performed in accordance with the guidelines of the Canadian Council on Animal Care. Data were collected from 125 male Wistar rats (300±500 g) anaesthetized with 1.4 g/kg (i.p.) urethane. The experimental protocol employed was as outlined in our previous study (Materi et al., 2000) with slight modi®cations. Brie¯y, a microdialysis probe (membrane length 2 mm, 0.5 mm outer diameter, molecular cutoff 30 kDa; Bioanalytical Systems (BAS), West Lafayette, Indiana, USA) was lowered vertically into the barrel ®eld of somatosensory cortex (coordinates 1.4 mm posterior and 5.0 mm lateral to bregma, 2.8 mm ventral to the dural surface). The probe was continuously perfused at a rate of 2 mL/min with arti®cial cerebrospinal¯uid to which atropine (10 mM; Sigma, Oakville, Ontario, Canada) and neostigmine methylsulphate (10 mM; Sigma) were added. The tip of a concentric bipolar stimulating electrode (250 mm tip diameter; Frederick Haer and Co., Brunswick, Maine, USA) was positioned within the pedunculopontine tegmental nucleus (PPT; coordinates 8.4 mm posterior and 2.0 mm lateral to bregma, 6.7 mm ventral to the pial surface). Sample collection commenced following a 90-min equilibration period.
As in our previous study (Materi et al., 2000) , each sample was collected over a 20-min period. Following three or four baseline samples, one sample was collected during electrical stimulation of the PPT. The PPT was stimulated using a 1-s stimulus train (0.2 ms, 100 Hz, 400 mA) applied once per min for 20 min (Rasmusson et al., 1994) . Following this, four samples were collected during which the amount of ACh present in the cortex returned to baseline levels. The dialysis perfusate was then switched to perfusate containing the drug being tested and this perfusate remained present for the remainder of the experiment. One sample collected in the presence of the drug was used to determine the effect of the drug on spontaneous ACh release. Following this, the PPT was stimulated using the same parameters as outlined above. This sample was used to determine the effect of the drug on synaptically evoked ACh release. Two or three poststimulation samples were then collected. Control animals were not exposed to any drugs.
Acetylcholine assay
Each sample was analysed for ACh content using high-performance liquid chromatography (HPLC) with electrochemical detection (Waters, Mississauga, Ontario, Canada) as described previously (Materi et al., 2000) . Data were collected and analysed using Powerchrome software (Castle Hill, New South Wales, Australia). The system was calibrated for each experiment using standard solutions containing 1, 2 and 4 pmol of ACh. The detection limit was » 0.1 pmol.
Adenosine assay
The samples derived from experiments examining the effects of glutamate alone or the simultaneous delivery of glutamate and caffeine were assayed for both ACh and adenosine. To obtain a suf®cient volume for each assay, these samples were diluted with arti®cial cerebrospinal¯uid (1 : 1 v/v), mixed vigorously, and then divided equally into two halves. One half was assayed for ACh content as outlined above. The second half was assayed for adenosine content using the protocol outlined by Pazzagli et al. (1994) with modi®cations. Brie¯y, for each microlitre of sample to be analysed for adenosine, 0.125 mL of chloroacetaldehyde (4.5%) was added. The adenosine/chloroacetaldehyde sample was then tightly sealed and placed in boiling water for 20 min. Following this, the samples were stored for up to one week at ±20°C. Each sample was assayed using HPLC with a Nova-Pak C 18 column (4 mm; Waters) and ultraviolet¯uorescence detection (Waters) at an excitation wavelength of 280 nm and a long-pass emission above 399 nm. The mobile phase consisted of a 50-mM acetate buffer (pH adjusted to 4.5 with acetic acid) containing 10% (v/v) acetonitrile and 2.4 mM 1-octanesulphonic acid sodium salt (Sigma) and was delivered at a rate of 0.7 mL/min. The amount of adenosine present in each sample was analysed by comparison of peak heights to adenosine standards of known concentration. The limit of detection was 60 nmol.
Histology
The placement of the microdialysis probe and stimulating electrode were examined histologically as described previously (Materi et al., 2000) . Forebrain sections containing the microdialysis probe track were stained with cresyl violet, and brainstem sections containing the stimulating electrode track were processed histochemically for nicotinamide adenine dinucleotide phosphate (NADPH)-diaphorase activity, a selective marker for cholinergic neurons within the mesopontine tegmentum (Vincent et al., 1983) .
Data analysis
Values were expressed as means T SEM, and probabilities < 0.05 were considered statistically signi®cant. Changes in spontaneous ACh release due to drugs delivered intracortically by reverse dialysis were examined by comparing the ®rst sample collected during drug delivery without PPT stimulation to the sample immediately preceding it. Differences in the amount of ACh collected were compared using a paired Student's t-test.
To examine the amount of evoked release, the absolute amount of ACh detected in the sample immediately prior to PPT stimulation was subtracted from the absolute amount of ACh detected during stimulation for both stimulation trials (E1 and E2), and the mean ratio of E2 to E1 was calculated for each group. The effect of drug application on synaptically evoked ACh release was investigated by comparing the E2/E1 ratio of the control group, which was not exposed to any drug, to the same ratio calculated from each experimental group. The differences in the ratios between the control and experimental groups were assessed by analysis of variance. Post hoc comparisons were performed using Fisher's protected least signi®cant difference test (PLSD).
Differences in cortical adenosine levels before and after delivery of glutamate, with or without caffeine, were determined using Student's t-test. Other speci®c comparisons are described in the results section.
Chemicals
The following chemicals were used: L-glutamic acid (Sigma); caffeine (BDH Chemicals, Toronto, Ontario, Canada); L-transpyrrolidine-2,4-dicarboxylic acid (L-trans-2,4-PDC; Tocris, Ballwin, MO, USA); N-methyl-D-aspartic acid (NMDA; Research Biochemicals International (RBI), Natick, MA, USA); a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA; Cambridge Research Biochemicals, Wilmington, DE, USA); 6,7-dinitroquinoxaline-2,3-dione (DNQX; RBI); (+/±)-3-(2-carboxypiperazin-4yl)-propyl-1-phosphonic acid (CPP; RBI); (±)-bicuculline methiodide (RBI); phaclofen (RBI); and 3-hydroxy-5-aminomethylisoxazole hydrobromide (muscimol; RBI). All of these drugs were dissolved in perfusate with the exception of DNQX which was dissolved initially in dimethylsulfoxide (DMSO; Sigma) and then diluted to the desired concentration with perfusate yielding a ®nal DMSO concentration of 1%. We demonstrated in a previous study (Materi et al., 2000) that 1% DMSO has no effect on either spontaneous or PPT stimulationevoked cortical ACh release. As in previous studies using microdialysis (e.g. Materi et al., 2000) , concentrations used were approximately 10 Q greater than those reported in in vitro studies measuring neurotransmitter release from brain slices. This was necessary due to the incomplete permeability of the microdialysis membrane and the poor diffusion of some analytes through tissue.
Results

Spontaneous vs. PPT stimulation evoked cortical acetylcholine release
The mean basal amount of ACh present in the cortex prior to the ®rst PPT stimulation was 0.49 T 0.06 pmol per 20-min sample. During stimulation of the PPT, the amount of ACh collected from the cortex increased signi®cantly (t 124 = 12.21, P < 0.0001) to an average of 2.41 T 0.20 pmol per 20-min sample. These values were comparable to those reported in previous studies (Rasmusson et al., 1994; Materi et al., 2000) . This con®rms that electrical stimulation of the PPT is a highly effective method for increasing cortical ACh release in vivo.
The effects of repeated PPT stimulation on cortical ACh release were examined in six control animals. The amount of cortical ACh released during the second stimulation was slightly, but not signi®cantly, greater than the amount released during the ®rst stimulation (E2/E1 = 1.16 T 0.12). This suggests that repeated exposure to electrical stimulation does not damage the PPT or alter the ACh releasing ability of basal forebrain neurons. Any observed changes to the E2/E1 ratio in the experimental groups must therefore be due to local effects of the drugs delivered by reverse dialysis.
Glutamate inhibits evoked acetylcholine ef¯ux in the cortex
To examine the effect of the glutamate on spontaneous ACh release, the ®rst sample collected during drug delivery was compared to the sample obtained immediately prior to it. Glutamate (0.1, 1 or 10 mM) had no signi®cant detectable effect on spontaneous cortical ACh release (predrug vs. drug, mean T SEM pmol: 0.1 mM glutamate, 0.55 T 0.26 vs. 0.50 T 0.17; 1 mM glutamate, 0.09 T 0.06 vs. 0.12 T 0.07; 10 mM glutamate, 0.05 T 0.05 vs. 0.26 T 0.10).
The effects of glutamate on PPT stimulation-evoked cortical ACh release were determined by comparing the E2/E1 ratios calculated from the groups exposed to different concentrations of glutamate to the same ratio calculated from the control group. As shown in Fig. 1 , glutamate produced a concentration-dependent decrease in evoked cortical ACh release. Whilst application of 0.1 mM glutamate did not alter evoked ACh ef¯ux, delivery of 1 and 10 mM glutamate yielded mean E2/E1 ratios that were 62 and 32% of the control value, respectively, representing a signi®cant decrease in evoked ACh release (F 3,19 = 6.89, P < 0.01; Fisher's PLSD: control vs. 1 and 10 mM glutamate, respectively, P < 0.05). This suggests that exogenously applied glutamate acts intracortically to inhibit evoked ACh release.
Inhibition of endogenous glutamate uptake reduces evoked ACh release
A previous microdialysis study demonstrated that infusion of the glutamate transport blocker L-trans-2,4-PDC increased cortical glutamate levels in vivo (Semba & Wakuta, 1998) . We found that infusion of L-trans-2,4-PDC into the cortex did not alter spontaneous ACh release (predrug vs. drug, 0.40 T 0.11 vs. 0.70 T 0.20 pmol), but signi®cantly reduced PPT stimulation-induced ACh release (t 8 = 3.21, P < 0.05; Fig. 1 ). The mean E2/E1 ratio calculated from the group exposed to the glutamate uptake blocker was 47% of the control value, comparable to the effects of exogenous glutamate described above. Thus, the effects of exogenous glutamate on cortical ACh ef¯ux was mimicked by the glutamate uptake inhibitor L-trans-2,4-PDC.
Ionotropic glutamate receptors mediate the inhibitory effects of glutamate on evoked ACh release
To determine which receptors mediate glutamate-induced inhibition of ACh release, the effects of selective ionotropic glutamate receptor agonists and antagonists were examined. Spontaneous cortical ACh ef¯ux was affected neither by NMDA (average ACh release in pmol predrug vs. drug: 0.025 mM NMDA, 0.56 T 0.09 vs. 0.50 T 0.08; 0.1 mM NMDA, 0.22 T 0.08 vs. 0.27 T 0.13; 0.3 mM NMDA, 0.26 T 0.13 vs. 0.09 T 0.06; 1 mM NMDA, 0.20 T 0.08 vs. 0.20 T 0.09) nor AMPA (10 mM AMPA, 0.38 T 0.14 vs. 0.15 T 0.12; 100 mM AMPA, 0.30 T 0.14 vs. 0.15 T 0.12). As shown in Fig. 2A , delivery of 1 mM NMDA (but not 0.025, 0.1 or 0.3 mM) by reverse dialysis signi®cantly reduced evoked cortical ACh release (F 4,21 = 4.97, P < 0.01; Fisher's PLSD: control vs. 1 mM NMDA, P < 0.01). AMPA at 100 mM, but not 10 mM, also signi®cantly reduced cortical ACh release evoked by PPT stimulation (F 2,12 = 5.56, P < 0.05; Fisher's PLSD: control vs. 100 mM AMPA, P < 0.01; Fig. 2B ). This suggests that both NMDA and AMPA receptors are involved in the glutamate-induced inhibition of evoked ACh release.
To test this possibility further, the effect of glutamate (1 mM) on ACh ef¯ux was tested in the presence of the non-NMDA receptor antagonist DNQX or the NMDA receptor antagonist CPP. Infusion of DNQX (0.1 mM) or CPP (0.1 mM) alone did not affect spontaneous (average release in pmol predrug vs. drug: 0.1 mM DNQX, 0.34 T 0.21 vs. 0.16 T 0.07; 0.1 mM CPP, 0.33 T 0.23 vs. 0.19 T 0.15) or evoked ACh release (Fig. 3) .
Simultaneous delivery of DNQX and 1 mM glutamate produced a mean E2/E1 ratio that was 25% greater than the same ratio calculated from the group that received glutamate alone (Fig. 3 ). Whilst this difference was not statistically signi®cant, this ratio was also not signi®cantly different from the ratio calculated from the control group. Higher concentrations of DNQX were not used due to the possibility of nonspeci®c effects (Drejer & Honore Â, 1988) . These results suggest that infusion of 0.1 mM DNQX only partially antagonized the inhibitory effect of glutamate.
As shown in Fig. 3 , CPP fully antagonized the inhibitory effects of 1 mM glutamate on evoked cortical ACh release. The E2/E1 ratio obtained from the group exposed to both CPP and glutamate was signi®cantly greater than the same ratio obtained from the group exposed to glutamate alone, but not signi®cantly different from the control value (F 2,14 = 3.78, P < 0.05; Fisher's PLSD: 1 mM glutamate vs. 1 mM glutamate plus 0.1 mM CPP, P < 0.05).
The inhibitory effects of glutamate are not mediated by activation of adenosine receptors
Glutamate is known to increase extracellular adenosine concentrations in the cortex (Hoehn & White, 1989; Bennett et al., 1999) , and we recently demonstrated that adenosine inhibits evoked cortical ACh release in urethane-anaesthetized rats (Materi et al., 2000) . To determine if the inhibitory response to glutamate was due to an increase in extracellular adenosine levels and subsequent activation of adenosine receptors, the effect of glutamate in the presence of the broad spectrum adenosine receptor antagonist caffeine was examined. These samples were assayed for both ACh and adenosine content.
In addition to inhibiting evoked ACh release as described above, glutamate (1 and 10 mM) produced a signi®cant increase in extracellular adenosine levels. Speci®cally, glutamate (1 mM) increased basal adenosine levels from 19.2 to 50.9 pmol per 20-min sample (t 4 = 4.72, P < 0.01). Similarly, samples collected prior to delivery of 10 mM glutamate contained an average of 19.8 pmol per 20-min sample and this increased signi®cantly to 193.5 pmol per 20-min sample following drug delivery (t 5 = 3.88, P < 0.05).
Caffeine (0.5 mM) did not antagonize the inhibitory effects of glutamate (1 and 10 mM) on evoked ACh release (see Fig. 4 ). The E2/E1 ratios calculated from the groups exposed to both caffeine and glutamate were similar to those calculated from the groups exposed to glutamate alone (Fig. 1) . Administration of caffeine did not block the signi®cant increase in extracellular adenosine levels caused by glutamate (caffeine plus 1 mM glutamate: t 4 = 5.04, P < 0.01; caffeine plus 10 mM glutamate: t 3 = 5.55, P < 0.05).
Glutamate-mediated inhibition of evoked ACh release involves GABAergic systems
Local GABAergic inhibition of cortical ACh release was reported recently (Giorgetti et al., 2000) . To determine if extracellular GABA in the cortex is involved in the inhibition of ACh release, the effects of glutamate (1 mM) on evoked cortical ACh release was tested in the presence of the GABA A receptor antagonist bicuculline or the GABA B receptor antagonist phaclofen.
The GABA A receptor antagonist bicuculline (0.05 mM) affected spontaneous ACh release. Application of bicuculline (0.05 mM) signi®cantly increased spontaneous cortical ACh release, from an average basal release of 0.35 T 0.05 to 0.91 T 0.12 pmol per 20-min sample (t 4 = 3.42, P < 0.05). This suggests the presence of tonic inhibition of cortical ACh release by GABA A -receptor activation under the present experimental conditions.
The simultaneous delivery of bicuculline (0.05 mM) and glutamate (1 mM) did not alter spontaneous ACh release (predrug vs. drug, 0.76 T 0.27 vs. 1.66 T 0.34 pmol) but did reverse the inhibitory effects of glutamate on evoked cortical ACh release (Fig. 5A) . The ratio obtained from the group exposed to both bicuculline and glutamate was signi®cantly greater than the ratio obtained from the 1 mM glutamate alone group (F 3,18 = 3.57, P < 0.05; Fisher's PLSD: 1 mM glutamate vs. 1 mM glutamate and 0.05 mM bicuculline, P < 0.05) but not signi®cantly different from the control group ratio.
Delivery of the GABA B receptor antagonist phaclofen (0.05 mM) alone or in combination with 1 mM glutamate did not have any effect on basal ACh release (in pmol predrug vs. drug: 0.05 mM phaclofen, 0.20 T 0.09 vs. 0.21 T 0.10; 0.05 mM phaclofen and 1 mM glutamate, 0.59 T 0.15 vs. 1.22 T 0.37). Simultaneous delivery of phaclofen and glutamate yielded a mean E2/E1 ratio that was 35% greater than that of the group exposed to glutamate alone but this was not statistically signi®cant (Fig. 5A) .
To examine the involvement of GABA A receptors further, the effects of the GABA A receptor agonist muscimol were tested. Application of muscimol by reverse dialysis did not alter spontaneous cortical ACh release (in pmol predrug vs. drug: 20 mM muscimol, 0.68 T 0.52 vs. 0.20 T 0.13; 100 mM muscimol, 0.52 T 0.24 vs. 0.39 T 0.15). However, as shown in Fig. 5B , 100 mM muscimol (but not 20 mM) signi®cantly reduced synaptically evoked ACh ef¯ux in the cortex (F 2,14 = 4.44, P < 0.05; Fisher's PLSD: control vs. 100 mM muscimol, P < 0.05).
Histology
The placement of the microdialysis probe within the grey matter of the barrel ®eld of the somatosensory cortex, and of the tip of the stimulating electrode within 0.2 mm of the PPT, was con®rmed in every animal by histological examination.
Discussion
The main ®ndings of this study are: (i) glutamate has no detectable effect on spontaneous cortical ACh release, but inhibits evoked ACh release in a concentration-dependent manner; (ii) this inhibition can be mimicked by the glutamate transporter blocker L-trans-2,4-PDC, as well as by the ionotropic glutamate receptor agonists NMDA and AMPA, and can be antagonized partially by DNQX and fully by CPP; and (iii) glutamate-induced inhibition of evoked cortical ACh ef¯ux was fully antagonized by the GABA A receptor antagonist bicuculline and partially by the GABA B receptor antagonist phaclofen. These ®ndings suggest that glutamate can inhibit evoked cortical ACh release via an indirect circuit involving intracortical GABAergic receptors.
Technical considerations
Advantages and limitations of the use of urethane-anaesthetized animals, and the addition of atropine to perfusate, have been discussed previously (Rasmusson et al., 1992; Materi et al., 2000) . Brie¯y, urethane-anaesthetized animals provide a steady baseline of ACh release upon which drug effects can be tested without confounds associated with behavioural changes in unanaesthetized animals. The use of anaesthetics, however, reduced the basal level of ACh, and it was necessary to add neostigmine and atropine to the perfusate (Rasmusson et al., 1992 (Rasmusson et al., , 1994 Materi et al., 2000) . Neostigmine is an acetylcholinesterase inhibitor and increases extracellular ACh levels. This increases activation of muscarinic, presumably M2, autoreceptors present on cholinergic terminals, and this would reduce ACh release (Moor et al., 1998) . Atropine was therefore added to increase ACh recovery by blocking these autoreceptors. In the present study, atropine also served a second purpose. ACh is known to inhibit the release of glutamate (Hasselmo & Bower, 1992; Kimura & Baughman, 1997) and GABA (Hasselmo & Bower, 1992; Ferraro et al., 1997; Kimura & Baughman, 1997) in the cerebral cortex by activating presynaptic muscarinic receptors. Therefore, the inhibition of these feedback loops by atropine also made the results more straightforward to interpret. Despite these advantages offered by the use of atropine, the possible interaction between muscarinic receptors and glutamate and GABA receptors should be considered. In the present study, none of the receptor agonists and antagonists, with the exception of bicuculline, had any detectable effect on basal ACh release. This suggests that, at least at the concentrations used, these drugs were unlikely to interact with muscarinic receptor activation directly. Furthermore, we are not aware of any report in the literature on direct modulation of muscarinic receptor activation by glutamate, GABA or their agonists. Therefore, the modulation of evoked ACh release by these drugs through their direct modulation at muscarinic receptors would seem unlikely, although it cannot be totally excluded.
One additional concern is the potential excitotoxic damage of intracortical neurons by glutamate and its analogues. However, Vanicky Â et al. (1998) examined rat cerebral cortex 24 h following 20-min delivery by reverse dialysis, and found that NMDA caused lesions when administered at concentrations of 10 mM or higher. The highest concentration of NMDA used in the present study was 10-fold less and therefore damage due to NMDA is likely to be negligible.
Comparison with previous studies using ionotropic glutamate receptor agonists
As stated above, activation of cortical AMPA and NMDA receptors reduced synaptically evoked, but not spontaneous, cortical ACh ef¯ux. The lack of inhibitory effect on spontaneous ACh release is likely to be due to already low basal ACh levels in anaesthetized rats, levels which can be close to the detection threshold. The present results with evoked release are consistent with those reported by Hasegawa et al. (1993) who demonstrated in unanaesthetized rats that local administration of NMDA to the cortex inhibited ACh ef¯ux evoked by the systemic delivery of an NMDA receptor antagonist. In contrast, Lodge & Johnston (1985) reported that application of NMDA, quisqualate and kainate enhanced basal ACh ef¯ux from cortical slices. Ulus et al. (1992) also reported the enhancement of basal ACh release from rat cortical slices following NMDA application. It is not immediately clear why the results should vary depending upon whether ACh is collected from cortical slices or from the cortex of an intact animal regardless of anaesthesia. However, it is possible that the absence of subcortical neuronal systems and other factors associated with in vitro conditions contributed to the discrepancy.
The inhibitory effects of glutamate on evoked ACh release is not mediated by adenosine
We tested the possibility that intracortical glutamate inhibited evoked ACh release via an indirect mechanism that involved other neuromodulatory agents, namely adenosine and GABA. Glutamate is known to increase extracellular cortical adenosine levels (Hoehn & White, 1989; Bennett et al., 1999) and our previous study (Materi et al., 2000) demonstrated that adenosine inhibits evoked cortical ACh release in a concentration-dependent manner in urethaneanaesthetized rats via activation of the A 1 adenosine receptor. In the present study, however, despite increased extracellular adenosine levels, simultaneous delivery of the broad-spectrum adenosine receptor antagonist caffeine did not reverse the effects of glutamate on PPT stimulation-evoked cortical ACh release. We have demonstrated previously that administration of 0.5 mM caffeine by reverse dialysis has no effect on spontaneous or PPT stimulation-evoked cortical ACh release but was able to antagonize the inhibitory effects of adenosine transporter inhibitors on evoked ACh release (Materi et al., 2000) . In addition to this effect, caffeine antagonized the inhibitory actions of the selective A 1 receptor agonist
Rasmusson and K. Semba, unpublished observations). The activation of the A 1 adenosine receptor is known to inhibit adenylyl cyclase activity as well as calcium entry, and to increase potassium conductance (for a review, see Williams, 1987) . The fact that caffeine did not have any effect on glutamate-induced inhibition of cortical ACh release suggests that glutamate-induced inhibition is independent of, and/or signi®cantly more potent than, adenosine receptor-mediated inhibition.
Inhibition of ACh release by glutamate: involvement of GABAergic neurons
The observed inhibitory effect of glutamate on evoked cortical ACh release is likely to involve intracortical GABAergic receptors. This conclusion is based on the observation that the inhibitory effects of glutamate on evoked ACh release could be completely reversed by the simultaneous delivery of the GABA A receptor antagonist bicuculline. Furthermore, administration of bicuculline enhanced spontaneous ACh release suggesting the presence of a tonic, GABAmediated inhibitory tone. These results are consistent with the ®ndings of Giorgetti et al. (2000) , who demonstrated GABA-induced inhibition of cortical ACh release in freely moving rats. Because glutamate had no effect on evoked ACh release in the presence of bicuculline, this suggests that glutamate does not act directly on intracortical cholinergic terminals. This interpretation is consistent with previous report that NMDA receptor-immunoreactive ®bres are not particularly enriched in the rat cerebral cortex (Conti et al., 1997; Paquet & Smith, 2000) .
The sensitivity of glutamate-induced inhibition of ACh release to GABA receptor antagonists suggests that the inhibition may be due to the effects of GABA released in response to activation of ionotropic glutamate receptors on GABAergic cortical neurons. Previous studies have shown that application of ionotropic glutamate receptor agonists increases GABA release in vitro from cultured cortical interneurons Glutamate inhibits evoked ACh release 43 (Drejer et al., 1987) and in vivo from the hippocampus and striatum of freely moving rats (Hata et al., 1997) . In the cortex, GABA may originate from intracortical interneurons or from the terminals of GABAergic basal forebrain projection neurons (Freund & Meskenaite, 1992) . However, presynaptic facilitation of GABA release from ®bre terminals of GABAergic basal forebrain neurons (or terminals of GABAergic interneurons) by NMDA receptor activation seems unlikely because only sparse GABAergic terminals were immunoreactive for the NMDAR1 subunit of the NMDA receptor (DeBiasi et al., 1996; Conti et al., 1997; Paquet & Smith, 2000) . Therefore, it is most likely that in the present study infusion of ionotropic glutamate receptor agonists increased cortical GABA levels by activating GABAergic cortical neurons, and GABA in turn inhibited ACh release via presynaptic GABA A , and possibly GABA B , receptors present on cholinergic terminals. Activation of the presynaptic GABA A receptors is known to be capable of reducing neurotransmitter ef¯ux by hyperpolarizing nerve terminals via an increase in Cl ± conductance and thereby reducing the probability of neurotransmitter release (for a review, see MacDermott et al., 1999) .
It is possible that GABA B receptors are also present on cholinergic terminals, and activation of these presynaptic receptors by GABA could open potassium channels and/or suppress calcium channel activation, thus inhibiting ACh release. However, this inhibition would not be as powerful as GABA A receptor-mediated inhibition because the GABA B antagonist only partially blocked glutamateevoked inhibition of ACh release. It has been suggested that activation of GABA B receptors on GABAergic neurons participates in autoinhibition of GABA release from intracortical neurons and results in increased cortical ACh release (Giorgetti et al., 2000) . This mechanism is unlikely to play a crucial role in the present experimental condition because administration of the GABA B receptor antagonist phaclofen partially reversed, rather than enhanced, the glutamate-induced inhibition of ACh release.
Previous in vitro studies reported that GABA has a facilitatory effect on cortical ACh release (Bianchi et al., 1982; Bonanno et al., 1991) . However, our in vivo results demonstrate that GABA mediates not only a tonic inhibitory tone on cortical ACh release but is also responsible for the reduction in evoked cortical ACh release. This is consistent with the recent report by Giorgetti et al. (2000) . The reason for the discrepancy between the in vitro and in vivo results is unclear.
That GABA can mediate the indirect inhibitory actions of other neurotransmitters on cortical ACh ef¯ux has been suggested. Previous studies have shown that the inhibitory effects of serotonin (Ramõ Ârez et al., 1996) , histamine (Giorgetti et al., 1997) , and norepinephrine (Beani et al., 1986) on cortical ACh release are mediated by GABA. It has also been demonstrated that glutamate can regulate neurotransmitter ef¯ux via a polysynaptic circuit involving GABAergic neurons. Becquet et al. (1990) , using a push-pull cannula, demonstrated that glutamate-induced reduction in serotonin release from the caudate nucleus of rats was antagonized by bicuculline. A glutamatergic± GABAergic circuit within the septum of the rat has also been shown to regulate cortical ACh release . Speci®cally, increased cortical ACh ef¯ux due to local administration of CPP to the septum was blocked by the simultaneous delivery of muscimol . The present results suggest that a similar circuit is present within the cerebral cortex at the terminal level of basal forebrain cholinergic neurons.
Functional implications
Within the cortex, the main effect of ACh is to increase the response of cortical neurons to speci®c input as demonstrated by an increase in the signal-to-noise ratio (for a review, see McCormick, 1990 ).
Consistent with this notion, Metherate & Ashe (1995) have shown that in the rat auditory cortex in vivo, the spontaneously released ACh can preferentially depress responses to weak, compared to strong, inputs through activation of muscarinic receptors. Interestingly, the acetylcholinesterase inhibitor eserine depressed the non-NMDA receptor-mediated, but not the NMDA receptor-mediated, component of the response, whereas carbachol still depressed the latter. These results led the authors to suggest that the activation of NMDA receptors may reduce spontaneous ACh release, either by a postsynaptic mechanism and a diffusible messenger, or a direct presynaptic mechanism involving presynaptic NMDA receptors on cholinergic terminals. The present results are, ®rst of all, consistent with this inhibitory effect of NMDA on synaptic responses and, in addition, suggest that this inhibition might involve an activation of GABAergic interneurons and subsequent release of GABA. Thus, synaptically released glutamate could activate GABAergic neurons to release GABA locally, and if GABA diffuses extrasynaptically in suf®cient quantities, it could activate presynaptic GABA A receptors on cholinergic terminals, thus inhibiting ACh release. This action of glutamate via GABAergic interneurons might provide an indirect negative feedback to regulate the increased signal-to-noise ratio induced by ACh postsynaptically. A similar inhibitory action of NMDA has also been reported at systems and behavioural levels. Ludvig et al. (1992) have shown that administration of NMDA by reverse dialysis at concentrations equivalent to those used in the present study resulted in the depression of both behavioural and local cortical EEG activity.
Whilst less is known about speci®c mechanisms, ACh has also been shown to induce long lasting changes in the response properties of cortical neurons to a variety of sensory inputs, including touch (Metherate et al., 1987) , audition (Metherate & Weinberger, 1990) and vision (Sillito & Kemp, 1983) . It is also suggested that ACh mediates deafferentation-induced synaptic plasticity (Sachdev et al., 1998) and reorganization (Kilgar & Merzenich, 1998) . It is possible that ACh provides a feedback that serves to regulate and optimize these functional adaptations. Such regulation might be mediated by the glutamatergic inputs to GABAergic neurons from pyramidal neurons, excitatory intrinsic neurons and/or thalamocortical afferents (Douglas & Martin, 1998) .
Increasing evidence suggests that neurotransmitters, including glutamate and GABA, can spill over and act at extrasynaptic receptors away from the original site of release (Bergles et al., 1999; Mitchell & Silver, 2000) . Consistent with this notion, GABA A receptors are found both synaptically and extrasynaptically, and these receptors appear to have different pharmacokinetics (Nusser et al., 1995; Brickley et al., 1999) . Recent evidence suggests that tonic activation of extrasynaptic GABA A receptors plays an important role in optimizing neuronal excitability for salient input (Brickley et al., 2001) . It is possible therefore that the inhibitory effect of glutamate on evoked ACh release re¯ects an inhibitory feedback mechanism for maintaining optimal levels of ACh release. In the light of the ®ndings that GABA mediates the inhibitory effects of glutamate, histamine and noradrenaline on cortical ACh release (the present study; Beani et al., 1986; Ramõ Ârez et al., 1996; Giorgetti et al., 1997) , GABAergic interneurons in the cortex appear to be at a strategic site for optimizing cortical ACh release to regulate cortical neuronal excitability for adaptive behaviour. 
Abbreviations
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